Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.2
3.0
Journals
Neurology International
Special Issues
Exclusive Papers from the Editorial Board Members (EBMs) and Invited...
share announcement

Exclusive Papers from the Editorial Board Members (EBMs) and Invited Scholars of Neurology International

A special issue of Neurology International (ISSN 2035-8377).

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 5632

Special Issue Editors

Prof. Dr. Thomas Müller

E-Mail Website
Guest Editor
Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Berlin, Germany
Interests: neurology; psychiatry; pain; Parkinson's disease; multiple sclerosis
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Alan David Kaye

E-Mail Website
Guest Editor
Department of Anesthesiology, Louisiana State University, Shreveport, LA, USA
Interests: pharmacology; anesthesiology; pain management; pain medicine; opioids
Special Issues, Collections and Topics in MDPI journals
Dr. Elyse M. Cornett

E-Mail Website
Guest Editor
Department of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, USA
Interests: neuroscience; pharmacology; drug abuse; pain management; opioids
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As the Editorial Board Members of Neurology International, we are pleased to announce a Special Issue, entitled "Exclusive Papers from the Editorial Board Members (EBMs) and Invited Scholars of Neurology International". This Special Issue will be a collection of high-quality papers from the Editorial Board Members and invited scholars. The aim is to provide a venue for networking and communication between the journal and scholars in this field.

Both original research articles and comprehensive review papers are welcome, addressing current critical issues in the field, grounded in sound science and providing authoritative commentaries, as well as novel concepts. All papers will be published fully open access after successful peer review.

Prof. Dr. Thomas Müller
Prof. Dr. Alan David Kaye
Dr. Elyse M. Cornett
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Neurology International is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

12 pages, 1158 KiB  
Article
Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study
by Marcello Moccia, Giuseppina Affinito, Giuseppina Marrazzo, Tiziana Ciarambino, Paolo Di Procolo, Licia Confalonieri, Antonio Carotenuto, Maria Petracca, Roberta Lanzillo, Maria Triassi, Vincenzo Brescia Morra and Raffaele Palladino
Neurol. Int. 2024, 16(2), 394-405; https://doi.org/10.3390/neurolint16020029 - 29 Mar 2024
Viewed by 378
Abstract
Background: We aim to provide up-to-date real-world evidence on the persistence, adherence, healthcare resource utilization, and costs of multiple sclerosis (MS) by comparing ocrelizumab to other disease-modifying treatments (DMTs) and within different DMT sequences. Methods: We included 3371 people with MS who first [...] Read more.
Background: We aim to provide up-to-date real-world evidence on the persistence, adherence, healthcare resource utilization, and costs of multiple sclerosis (MS) by comparing ocrelizumab to other disease-modifying treatments (DMTs) and within different DMT sequences. Methods: We included 3371 people with MS who first received or switched DMT prescriptions from January 2018 to December 2022; they were identified through hospital discharge records, drug prescriptions, and exemption codes from the Campania Region (South Italy). We calculated persistence (time from the first prescription to discontinuation or switching to another DMT), adherence (proportion of days covered (PDC)), DMT costs, and MS hospital admissions and related costs. Results: The most frequently prescribed DMT was dimethyl fumarate (n = 815; age 38.90 ± 11.91 years; 69.5% females), followed by ocrelizumab (n = 682; age 46.46 ± 11.29 years; 56.3%); 28.8% of the patients treated with ocrelizumab were naïve to DMTs. Using ocrelizumab as a statistical reference, the risk of discontinuation was higher for other highly active (HR = 6.32; 95%CI = 3.16, 12.63; p < 0.01) and low-/medium-efficacy DMTs (HR = 10.10; 95%CI = 5.10, 19.77; p < 0.01); adherence was lower for other highly active DMTs (Coeff = −0.07; 95%CI = −0.10, −0.04; p < 0.01) and low-/medium-efficacy DMTs (Coeff = −0.16; 95%CI = −0.19, −0.14; p < 0.01). monthly DMT costs were higher for other highly active DMTs (Coeff = 77.45; 95%CI = 29.36, 125.53; p < 0.01) but lower for low-/medium-efficacy DMTs (Coeff = −772.31; 95%CI = −816.95, −727.66; p < 0.01). The hospital admissions and related costs of MS were similar between ocrelizumab, other highly active DMTs, and other low-/medium-efficacy DMTs, and with ocrelizumab as the first-line DMT after other highly active DMTs and after low-/medium-efficacy DMTs, which was possibly due to the low number of observations. Conclusions: From 2018 to 2022, ocrelizumab was among the most frequently prescribed DMTs, with 28.8% prescriptions to incident MS patients, confirming its relevance in clinical practice. Ocrelizumab was associated with the highest persistence and adherence, pointing towards its favorable benefit–risk profile. The costs of ocrelizumab were lower than those of other highly active DMTs. Full article
(This article belongs to the Special Issue Exclusive Papers from the Editorial Board Members (EBMs) and Invited Scholars of Neurology International)
►▼ Show Figures

Figure 1

14 pages, 3952 KiB  
Article
Mapping Motor Neuroplasticity after Successful Surgical Brachial Plexus Reconstruction Using Navigated Transcranial Magnetic Stimulation (nTMS)
by Gregor Durner, Ina Ulrich, Alexandra Gerst, Ralf Becker, Christian Rainer Wirtz, Gregor Antoniadis, Maria Teresa Pedro and Andrej Pala
Neurol. Int. 2024, 16(1), 239-252; https://doi.org/10.3390/neurolint16010016 - 01 Feb 2024
Viewed by 624
Abstract
Brachial plexus reconstruction (BPR) consists of the complex surgical restoration of nerve structures. To further understand the underlying motor cortex changes and evaluate neuroplasticity after a successful surgery, we performed a navigated transcranial magnetic stimulation (nTMS) study mapping the postoperative motor representation of [...] Read more.
Brachial plexus reconstruction (BPR) consists of the complex surgical restoration of nerve structures. To further understand the underlying motor cortex changes and evaluate neuroplasticity after a successful surgery, we performed a navigated transcranial magnetic stimulation (nTMS) study mapping the postoperative motor representation of the formerly plegic arm. We conducted a prospective nTMS study mapping the musculocutaneous nerve as a representative, prominent target of BPR including a patient (n = 8) and a control group (n = 10). Measurements like resting motor threshold (RMT), cortical motor area location, and size were taken. Mathematical analysis was performed using MATLAB 2022, statistical analysis was performed using SPSS 26, and nTMS mapping was performed using the Nexstim NBS 5.1 system. Mapping was feasible in seven out of eight patients. Median RMT on the affected hemisphere was 41% compared to 50% on the unaffected hemisphere and they were 37% and 36% on the left and right hemispheres of the control group. The motor area location showed a relocation of bicep brachii representation at the middle precentral gyrus of the corresponding contralateral hemisphere. Motor area size was increased compared to the control group and the patient’s unaffected, ipsilateral hemisphere. Understanding cortical reorganization is important for potential future treatments like therapeutic nTMS. The issue of motor neuroplasticity in patients with brachial plexus lesions is worth exploring in further studies. Full article
(This article belongs to the Special Issue Exclusive Papers from the Editorial Board Members (EBMs) and Invited Scholars of Neurology International)
►▼ Show Figures

Figure 1

30 pages, 4026 KiB  
Article
Atrial Fibrillation and Reperfusion Therapy in Acute Ischaemic Stroke Patients: Prevalence and Outcomes—A Comprehensive Systematic Review and Meta-Analysis
by Jay Patel and Sonu M. M. Bhaskar
Neurol. Int. 2023, 15(3), 1014-1043; https://doi.org/10.3390/neurolint15030065 - 25 Aug 2023
Cited by 1 | Viewed by 1253
Abstract
Atrial fibrillation (AF) significantly contributes to acute ischaemic stroke (AIS), yet its precise influence on clinical outcomes post-intravenous thrombolysis (IVT) and post-endovascular thrombectomy (EVT) has remained elusive. Furthermore, the overall prevalence of AF in AIS patients undergoing reperfusion therapy has not been clearly [...] Read more.
Atrial fibrillation (AF) significantly contributes to acute ischaemic stroke (AIS), yet its precise influence on clinical outcomes post-intravenous thrombolysis (IVT) and post-endovascular thrombectomy (EVT) has remained elusive. Furthermore, the overall prevalence of AF in AIS patients undergoing reperfusion therapy has not been clearly determined. Employing random-effects meta-analyses, this research aimed to estimate the pooled prevalence of AF among AIS patients undergoing reperfusion therapy, while also examining the association between AF and clinical outcomes such as functional outcomes, symptomatic intracerebral haemorrhage (sICH) and mortality. Studies comparing AF and non-AF patient groups undergoing reperfusion therapy were identified and included following an extensive database search. Forty-nine studies (n = 66,887) were included. Among IVT patients, the prevalence of AF was 31% (Effect Size [ES] 0.31 [95%CI 0.28–0.35], p < 0.01), while in EVT patients, it reached 42% (ES 0.42 [95%CI 0.38–0.46], p < 0.01), and in bridging therapy (BT) patients, it stood at 36% (ES 0.36 [95%CI 0.28–0.43], p < 0.01). AF was associated with significantly lower odds of favourable 90-day functional outcomes post IVT (Odds Ratio [OR] 0.512 [95%CI 0.376–0.696], p < 0.001), but not post EVT (OR 0.826 [95%CI 0.651–1.049], p = 0.117). Our comprehensive meta-analysis highlights the varying prevalence of AF among different reperfusion therapies and its differential impact on patient outcomes. The highest pooled prevalence of AF was observed in EVT patients, followed by BT and IVT patients. Interestingly, our analysis revealed that AF was significantly associated with poorer clinical outcomes following IVT. Such an association was not observed following EVT. Full article
(This article belongs to the Special Issue Exclusive Papers from the Editorial Board Members (EBMs) and Invited Scholars of Neurology International)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

18 pages, 421 KiB  
Review
Neurocognitive Impairment and Social Cognition in Parkinson’s Disease Patients
by Triantafyllos Doskas, Konstantinos Vadikolias, Konstantinos Ntoskas, George D. Vavougios, Dimitrios Tsiptsios, Polyxeni Stamati, Ioannis Liampas, Vasileios Siokas, Lambros Messinis, Grigorios Nasios and Efthimios Dardiotis
Neurol. Int. 2024, 16(2), 432-449; https://doi.org/10.3390/neurolint16020032 - 16 Apr 2024
Viewed by 293
Abstract
In addition to motor symptoms, neurocognitive impairment (NCI) affects patients with prodromal Parkinson’s disease (PD). NCI in PD ranges from subjective cognitive complaints to dementia. The purpose of this review is to present the available evidence of NCI in PD and highlight the [...] Read more.
In addition to motor symptoms, neurocognitive impairment (NCI) affects patients with prodromal Parkinson’s disease (PD). NCI in PD ranges from subjective cognitive complaints to dementia. The purpose of this review is to present the available evidence of NCI in PD and highlight the heterogeneity of NCI phenotypes as well as the range of factors that contribute to NCI onset and progression. A review of publications related to NCI in PD up to March 2023 was performed using PubMed/Medline. There is an interconnection between the neurocognitive and motor symptoms of the disease, suggesting a common underlying pathophysiology as well as an interconnection between NCI and non-motor symptoms, such as mood disorders, which may contribute to confounding NCI. Motor and non-motor symptom evaluation could be used prognostically for NCI onset and progression in combination with imaging, laboratory, and genetic data. Additionally, the implications of NCI on the social cognition of afflicted patients warrant its prompt management. The etiology of NCI onset and its progression in PD is multifactorial and its effects are equally grave as the motor effects. This review highlights the importance of the prompt identification of subjective cognitive complaints in PD patients and NCI management. Full article
(This article belongs to the Special Issue Exclusive Papers from the Editorial Board Members (EBMs) and Invited Scholars of Neurology International)
15 pages, 3065 KiB  
Review
Emerging Evidence of Golgi Stress Signaling for Neuropathies
by Remina Shirai and Junji Yamauchi
Neurol. Int. 2024, 16(2), 334-348; https://doi.org/10.3390/neurolint16020024 - 07 Mar 2024
Viewed by 752
Abstract
The Golgi apparatus is an intracellular organelle that modifies cargo, which is transported extracellularly through the nucleus, endoplasmic reticulum, and plasma membrane in order. First, the general function of the Golgi is reviewed and, then, Golgi stress signaling is discussed. In addition to [...] Read more.
The Golgi apparatus is an intracellular organelle that modifies cargo, which is transported extracellularly through the nucleus, endoplasmic reticulum, and plasma membrane in order. First, the general function of the Golgi is reviewed and, then, Golgi stress signaling is discussed. In addition to the six main Golgi signaling pathways, two pathways that have been increasingly reported in recent years are described in this review. The focus then shifts to neurological disorders, examining Golgi stress reported in major neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. The review also encompasses findings related to other diseases, including hypomyelinating leukodystrophy, frontotemporal spectrum disorder/amyotrophic lateral sclerosis, microcephaly, Wilson’s disease, and prion disease. Most of these neurological disorders cause Golgi fragmentation and Golgi stress. As a result, strong signals may act to induce apoptosis. Full article
(This article belongs to the Special Issue Exclusive Papers from the Editorial Board Members (EBMs) and Invited Scholars of Neurology International)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research, Review

12 pages, 1201 KiB  
Systematic Review
An Ecchordosis Physaliphora, a Rare Entity, Involving the Central Nervous System: A Systematic Review of the Literature
by Rajesh K. Gupta, Thejasvi A. Reddy, Ashutosh Gupta, Rohan Samant, Carlos A. Perez and Anam Haque
Neurol. Int. 2023, 15(4), 1200-1211; https://doi.org/10.3390/neurolint15040075 - 26 Sep 2023
Cited by 1 | Viewed by 1821
Abstract
Ecchordosis physaliphora (EP) is a benign notochordal remnant, which is often an incidental finding; however, it can rarely present with neurological symptoms. We performed a systematic review of the literature for cases of symptomatic EP published in PubMed, Web of Science and Embase [...] Read more.
Ecchordosis physaliphora (EP) is a benign notochordal remnant, which is often an incidental finding; however, it can rarely present with neurological symptoms. We performed a systematic review of the literature for cases of symptomatic EP published in PubMed, Web of Science and Embase from January 1982 to May 2023. This is the largest review to date and revealed 60 cases including ours. Headache (55%) and CSF rhinorrhea (32%) were the most frequent clinical manifestations. The majority of symptomatic EP lesions were located in the prepontine region (77%) and required surgical resection (75%). EP should be considered in patients with neurologic symptoms in the setting of prepontine or posterior sphenoid sinus lesions. While symptomatic patients often require surgical intervention, rare cases may respond to oral corticosteroids. Full article
(This article belongs to the Special Issue Exclusive Papers from the Editorial Board Members (EBMs) and Invited Scholars of Neurology International)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop